Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.42 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22886730 | 0.93 | L3MBTL1 (0.41) | FTOCAPN1L3MBTL1CTSBCTSS | |
| SCHEMBL22886539 | 0.92 | ALDH1A1 (0.42) | CAPN1ALDH1A1 | |
| SCHEMBL21854063 | 0.90 | CAPN1 (0.53) | CAPN1CTSBCTSS | |
| SCHEMBL20028431 | 0.90 | CAPN1 (0.53) | CAPN1CTSBCTSS | |
| SCHEMBL21410716 | 0.88 | FTO (0.42) | FTOCAPN1L3MBTL1ALDH1A1POLB | |
| SCHEMBL22886464 | 0.86 | ACE (0.42) | FTOL3MBTL1ALDH1A1TSHRHPGDS | |
| SCHEMBL22885869 | 0.86 | CAPN1 (0.40) | FTOCAPN1L3MBTL1 | |
| SCHEMBL22886543 | 0.86 | L3MBTL1 (0.46) | FTOCAPN1L3MBTL1HPGDSPOLB | |
| SCHEMBL22886508 | 0.86 | CAPN1 (0.45) | CAPN1ALDH1A1TSHRCTSBCTSS | |
| SCHEMBL21854216 | 0.85 | CAPN1 (0.52) | CAPN1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | BLADE THERAPEUTICS INC (US) | 2022-11-03 | — | — | US | disclosed |
| CN-112703188-A | Method for treating liver fibrosis using calpain inhibitor | 布莱德治疗公司 | 2021-04-23 | — | — | CN | disclosed |
| US-20210113560-A1 | METHOD OF TREATING FIBROTIC DISEASE | BLADE THERAPEUTICS INC (US) | 2021-04-22 | — | — | US | disclosed |
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
| CN-112204014-A | Calpain modulators and therapeutic uses thereof | 布莱德治疗公司 | 2021-01-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347173-A1 | METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS | CAPNS1, CAPN9, CAPN2 | FTO 4667/4885CAPN1 4/4885L3MBTL1 3900/4885 |
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | FTO 4735/4885CAPN1 3/4885L3MBTL1 3275/4885 |
| US-20210113560-A1 | METHOD OF TREATING FIBROTIC DISEASE | CAPN9, CAPNS1, CAPN1 | FTO 4438/4885CAPN1 3/4885L3MBTL1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.